共 50 条
Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1
被引:10
作者:
Paubelle, Etienne
[1
,2
,3
]
Plesa, Adriana
[4
]
Hayette, Sandrine
[4
]
Elhamri, Mohamed
[1
]
Zylbersztejn, Florence
[5
]
Hermine, Olivier
[5
,6
]
Salles, Gilles
[1
]
Thomas, Xavier
[1
]
机构:
[1] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Dept Clin Hematol, Pierre Benite, France
[2] Univ Lyon, Fac Med Lyon Sud Charles Merieux, Pierre Benite, France
[3] Hosp Civils Lyon, Fac Med Lyon Sud, Lab Biol & Modelisat Cellule, CNRS UMR5239,Ecole Normale Super Lyon, Pierre Benite, France
[4] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Dept Biol Hematol, Pierre Benite, France
[5] Imagine Inst, Lab Mol Mech Hematol Disorders & Therapeut Implic, Paris, France
[6] Hop Necker Enfants Malad, Dept Clin Hematol, Paris, France
关键词:
Acute myeloid leukemia;
All-trans-retinoic acid;
EVI1;
Leukemia stem cells;
MECOM;
ACUTE PROMYELOCYTIC LEUKEMIA;
YOUNGER ADULT PATIENTS;
ARSENIC TRIOXIDE;
DIFFERENTIATION PATHWAY;
STEM-CELLS;
EXPRESSION;
AML;
INHIBITION;
GENE;
MUTATIONS;
D O I:
10.1007/s40487-019-0095-9
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Introduction EVI1 (MECOM)-positive acute myeloid leukemia (AML) cells have shown in vitro sensitivity to all-trans-retinoic acid (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. Methods In this pilot study, we investigated the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. Results Seven of the 13 patients (53.8%) achieved complete remission (CR), and response can be combined with a decreased of the leukemia stem cell pool. Conclusion These primary results tend to confirm in vitro results and suggest that addition of ATRA might be of benefit in the treatment of patients with EVI1-positive AML.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 50 条